Efficacy and safety of aclidinium bromide in patients with COPD: A phase 3 randomized clinical trial in a Korean population

Sang Haak Lee, Jongmin Lee, Kwang Ha Yoo, Soo Taek Uh, Myung Jae Park, Sang Yeub Lee, Jae Yeol Kim, Deog Kyeom Kim, Seung Joon Kim, Kwan Ho Lee, Chul Gyu Yoo

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)


Background and objective Aclidinium bromide ('aclidinium') is a novel, inhaled long-acting muscarinic antagonist. Therapeutic effects of aclidinium on chronic obstructive pulmonary disease (COPD) have been demonstrated in Caucasian populations in several clinical trials. This was a randomized, double-blind, multi-centre phase-3 clinical trial to evaluate the efficacy and safety of aclidinium in a Korean population. Methods A total of 263 Korean patients with moderate-to-severe COPD were randomized to receive aclidinium (400-μg, bd) (Genuai) or placebo via a dry-powder inhaler. The primary end point was change in trough forced expiratory volume in one second (FEV1) at 12 weeks. Other lung function measurements, COPD exacerbation, health status (St George's Respiratory Questionnaire (SGRQ), dyspnoea (Transition Dyspnea Index (TDI) and safety were assessed throughout the study period. Results A significant improvement in trough FEV1 from baseline was shown with aclidinium compared with the placebo (0.126-L, P-<-0.0001). Significant improvements were also demonstrated in peak FEV1 (0.190-L, P-<-0.0001), SGRQ and TDI. Furthermore, aclidinium significantly reduced the prevalence of exacerbations (aclidinium, 5.4%; placebo, 15.6%, P-<-0.05), and the duration of exacerbations was shorter compared with placebo (rate ratio: 0.27; P-<-0.05). Aclidinium (400-μg) was well tolerated and the prevalence of adverse events was comparable with the placebo. Conclusions Inhaled aclidinium (400-μg) was shown to be safe and efficacious in Korean patients with moderate-to-severe COPD. Clinical trial registration: NCT01636401 at Clinicaltrials.gov This study demonstrated a favourable safety and efficacy profile of aclidinium bromide in Korean COPD patients that was similar to what was observed in Caucasian populations, suggesting no clinically significant ethnic difference.

Original languageEnglish
Pages (from-to)1222-1228
Number of pages7
Issue number8
Publication statusPublished - 2015 Nov
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2015 The Authors. Respirology published by Wiley Publishing Asia Pty Ltd on behalf of Asian Pacific Society of Respirology.


  • aclidinium bromide
  • cholinergic antagonist
  • chronic obstructive pulmonary disease
  • safety
  • treatment outcome

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Efficacy and safety of aclidinium bromide in patients with COPD: A phase 3 randomized clinical trial in a Korean population'. Together they form a unique fingerprint.

Cite this